ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,347.91
-0.09%
US Tech 100
18,518.40
-0.09%
Dow Jones
38,824.22
-0.16%
Brent Oil
79.33
-0.69%
Bitcoin
69,299.11
-2.08%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Roivant Sciences Ltd (ROIV)

  7. Roivant Sciences Ltd (ROIV) News

ROIV

Roivant Sciences (ROIV)

Roivant Sciences Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ROIV
DateTimeSourceHeadlineSymbolCompany
05/30/20249:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ROIVRoivant Sciences Ltd
05/30/20244:46PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ROIVRoivant Sciences Ltd
05/30/20247:45AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ROIVRoivant Sciences Ltd
05/30/20247:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ROIVRoivant Sciences Ltd
05/30/20247:00AMGlobeNewswire Inc.Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business UpdateNASDAQ:ROIVRoivant Sciences Ltd
05/22/20249:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ROIVRoivant Sciences Ltd
05/22/20249:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ROIVRoivant Sciences Ltd
05/22/20249:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ROIVRoivant Sciences Ltd
05/16/20244:05PMGlobeNewswire Inc.Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024NASDAQ:ROIVRoivant Sciences Ltd
04/02/20247:00AMGlobeNewswire Inc.Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 MillionNASDAQ:ROIVRoivant Sciences Ltd
03/26/20246:22PMPR Newswire (US)Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600NASDAQ:ROIVRoivant Sciences Ltd
02/13/20247:00AMGlobeNewswire Inc.Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business UpdateNASDAQ:ROIVRoivant Sciences Ltd
01/30/20244:05PMGlobeNewswire Inc.Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024NASDAQ:ROIVRoivant Sciences Ltd
12/20/20234:30PMGlobeNewswire Inc.Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ DiseaseNASDAQ:ROIVRoivant Sciences Ltd
12/14/20239:00AMGlobeNewswire Inc.Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel DiseaseNASDAQ:ROIVRoivant Sciences Ltd
11/28/20237:00AMGlobeNewswire Inc.Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class PotentialNASDAQ:ROIVRoivant Sciences Ltd
11/27/20238:00AMGlobeNewswire Inc.Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus ErythematosusNASDAQ:ROIVRoivant Sciences Ltd
11/13/20237:00AMGlobeNewswire Inc.Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business UpdateNASDAQ:ROIVRoivant Sciences Ltd
11/10/20238:00AMGlobeNewswire Inc.Roivant Announces Appointment of Mayukh Sukhatme to Its Board of DirectorsNASDAQ:ROIVRoivant Sciences Ltd
10/30/20235:30PMGlobeNewswire Inc.Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023NASDAQ:ROIVRoivant Sciences Ltd
10/23/20233:41PMDow Jones NewsTrending: Roche to Buy Telavant From Roivant and PfizerNASDAQ:ROIVRoivant Sciences Ltd
10/23/20237:18AMIH Market NewsMonday’s Wall Street Highlights: Philips, Chevron, Textainer, Okta, Roivant, and moreNASDAQ:ROIVRoivant Sciences Ltd
10/23/20234:16AMDow Jones NewsRoche to Buy Telavant From Roivant, Pfizer in Deal Worth Up to $7.25 Billion -- UpdateNASDAQ:ROIVRoivant Sciences Ltd
10/23/20231:50AMDow Jones NewsRoche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Billion DealNASDAQ:ROIVRoivant Sciences Ltd
10/23/20231:00AMGlobeNewswire Inc.Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From RoivantNASDAQ:ROIVRoivant Sciences Ltd
10/13/20238:00AMGlobeNewswire Inc.Covant Therapeutics Appoints Vincent Hennemand as Chief Executive OfficerNASDAQ:ROIVRoivant Sciences Ltd
09/26/20236:00AMGlobeNewswire Inc.Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD ResultsNASDAQ:ROIVRoivant Sciences Ltd
09/11/20238:00AMGlobeNewswire Inc.Roivant Announces Completion of Redemption of its Outstanding WarrantsNASDAQ:ROIVRoivant Sciences Ltd
08/17/20234:05PMGlobeNewswire Inc.Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding WarrantsNASDAQ:ROIVRoivant Sciences Ltd
08/14/20237:00AMGlobeNewswire Inc.Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business UpdateNASDAQ:ROIVRoivant Sciences Ltd
 Showing the most relevant articles for your search:NASDAQ:ROIV

Your Recent History

USOTC
BXLC
Bexil (PK)
COIN
ITZUSD
USOTC
TSUBF
Tsubota Laboratory (GM)
ASX
SMLL
BetaShares Capital
BIBX
XNKBTC
Ink Protocol
TSX
7030
Sprix
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved